

Anieta M Sieuwerts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7823081/publications.pdf>

Version: 2024-02-01

135
papers

17,273
citations

30070

54
h-index

14759

127
g-index

138
all docs

138
docs citations

138
times ranked

24606
citing authors

#	ARTICLE	IF	CITATIONS
1	The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer. <i>BMC Cancer</i> , 2022, 22, 165.	2.6	8
2	A pipeline for copy number profiling of single circulating tumour cells to assess inpatient tumour heterogeneity. <i>Molecular Oncology</i> , 2022, 16, 2981-3000.	4.6	6
3	Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests. <i>Oncogene</i> , 2022, 41, 3498-3506.	5.9	9
4	Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer. <i>BMC Cancer</i> , 2021, 21, 315.	2.6	18
5	Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 697572.	2.8	0
6	Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells. <i>European Journal of Cancer</i> , 2021, 150, 179-189.	2.8	47
7	Interconnectivity between molecular subtypes and tumor stage in colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 850.	2.6	14
8	Plasticity of Lgr5-Negative Cancer Cells Drives Metastasis in Colorectal Cancer. <i>Cell Stem Cell</i> , 2020, 26, 569-578.e7.	11.1	180
9	ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen. <i>Cancers</i> , 2020, 12, 802.	3.7	20
10	Optimization of Pancreatic Juice Collection: A First Step Toward Biomarker Discovery and Early Detection of Pancreatic Cancer. <i>American Journal of Gastroenterology</i> , 2020, 115, 2103-2108.	0.4	14
11	APOBEC3B Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer. <i>Cancers</i> , 2019, 11, 1062.	3.7	9
12	Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. <i>Cancers</i> , 2019, 11, 1212.	3.7	21
13	Generation of in situ sequencing based OncoMaps to spatially resolve gene expression profiles of diagnostic and prognostic markers in breast cancer. <i>EBioMedicine</i> , 2019, 48, 212-223.	6.1	29
14	Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 121, 48-54.	2.8	20
15	The circular RNome of primary breast cancer. <i>Genome Research</i> , 2019, 29, 356-366.	5.5	85
16	Proteome-wide onco-proteogenomic somatic variant identification in ER-positive breast cancer. <i>Clinical Biochemistry</i> , 2019, 66, 63-75.	1.9	3
17	<i>AR</i> splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel. <i>Molecular Oncology</i> , 2019, 13, 1795-1807.	4.6	23
18	Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation. <i>Nature Communications</i> , 2019, 10, 1749.	12.8	46

#	ARTICLE	IF	CITATIONS
19	Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 1083-1089.	5.1	27
20	An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 123-137.	2.8	15
21	PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 471-482.	3.1	17
22	An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 316-325.	2.8	15
23	T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression. <i>Acta Neuropathologica</i> , 2018, 135, 581-599.	7.7	63
24	Confirmation of a metastasis-specific microRNA signature in primary colon cancer. <i>Scientific Reports</i> , 2018, 8, 5242.	3.3	33
25	Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients. <i>Molecular Oncology</i> , 2018, 12, 48-57.	4.6	52
26	Analysis of clonal expansions through the normal and premalignant human breast epithelium reveals the presence of luminal stem cells. <i>Journal of Pathology</i> , 2018, 244, 61-70.	4.5	13
27	Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1st-line tamoxifen therapy in breast cancer. <i>Scientific Reports</i> , 2018, 8, 9657.	3.3	32
28	Gene length corrected trimmed mean of M-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons. <i>BMC Bioinformatics</i> , 2018, 19, 236.	2.6	105
29	Dendritic Cells Actively Limit Interleukin-10 Production Under Inflammatory Conditions via DC-SCRIPT and Dual-Specificity Phosphatase 4. <i>Frontiers in Immunology</i> , 2018, 9, 1420.	4.8	16
30	Functional <i>in vivo</i> Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. <i>Clinical Cancer Research</i> , 2018, 24, 6277-6287.	7.0	53
31	MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer. <i>Oncotarget</i> , 2018, 9, 24335-24346.	1.8	11
32	Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 4735-4743.	7.0	14
33	A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer. <i>Cancer Research</i> , 2017, 77, 3814-3822.	0.9	76
34	Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer. <i>American Journal of Pathology</i> , 2017, 187, 1648-1655.	3.8	23
35	Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer. <i>Scientific Reports</i> , 2017, 7, 2099.	3.3	33
36	HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. <i>Nature Medicine</i> , 2017, 23, 517-525.	30.7	769

#	ARTICLE	IF	CITATIONS
37	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. <i>Oncogene</i> , 2017, 36, 2737-2749.	5.9	34
38	Genomic Evolution of Breast Cancer Metastasis and Relapse. <i>Cancer Cell</i> , 2017, 32, 169-184.e7.	16.8	534
39	High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemo-naïve lymph node negative colon cancer patients. <i>PLoS ONE</i> , 2017, 12, e0185607.	2.5	14
40	Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer. <i>PLoS ONE</i> , 2017, 12, e0170536.	2.5	8
41	Progressive APOBEC3B mRNA expression in distant breast cancer metastases. <i>PLoS ONE</i> , 2017, 12, e0171343.	2.5	31
42	The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0161731.	2.5	15
43	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016, 534, 47-54.	27.8	1,760
44	mRNA expression profiles of colorectal liver metastases as a novel biomarker for early recurrence after partial hepatectomy. <i>Molecular Oncology</i> , 2016, 10, 1542-1550.	4.6	9
45	The topography of mutational processes in breast cancer genomes. <i>Nature Communications</i> , 2016, 7, 11383.	12.8	235
46	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. <i>Nature Communications</i> , 2016, 7, 12910.	12.8	119
47	The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. <i>Science Advances</i> , 2016, 2, e1601737.	10.3	175
48	Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. <i>Neoplasia</i> , 2016, 18, 647-653.	5.3	44
49	GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease. <i>Cancer Letters</i> , 2016, 376, 104-109.	7.2	22
50	An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 123.	2.6	25
51	APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 4746-4755.	7.0	59
52	Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 59058-59069.	1.8	37
53	Mitochondrial DNA content in breast cancer: Impact on <i>in vitro</i> and <i>in vivo</i> phenotype and patient prognosis. <i>Oncotarget</i> , 2016, 7, 29166-29176.	1.8	33
54	A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds. <i>PLoS ONE</i> , 2015, 10, e0144097.	2.5	6

#	ARTICLE	IF	CITATIONS
55	Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 821-827.	4.1	49
56	mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients. <i>Molecular Oncology</i> , 2015, 9, 920-932.	4.6	37
57	Integrative Analysis of Genomics and Proteomics Data on Clinical Breast Cancer Tissue Specimens Extracted with Acid Guanidinium Thiocyanate-Phenol-Chloroform. <i>Journal of Proteome Research</i> , 2015, 14, 1627-1636.	3.7	17
58	DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ER±-positive breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 693-703.	2.5	16
59	Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. <i>European Urology</i> , 2015, 68, 939-945.	1.9	223
60	Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes. <i>Molecular Oncology</i> , 2015, 9, 877-888.	4.6	16
61	Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. <i>Molecular Oncology</i> , 2015, 9, 1218-1233.	4.6	64
62	Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. <i>Cancer Letters</i> , 2015, 362, 36-44.	7.2	41
63	The Influence of Tissue Procurement Procedures on RNA Integrity, Gene Expression, and Morphology in Porcine and Human Liver Tissue. <i>Biopreservation and Biobanking</i> , 2015, 13, 200-206.	1.0	23
64	In Vitro and In Vivo Application of Radiolabeled Gastrin-Releasing Peptide Receptor Ligands in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 752-757.	5.0	49
65	Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1487-1493.	5.0	30
66	Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer. <i>Cancer Letters</i> , 2015, 356, 872-879.	7.2	28
67	Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. <i>Annals of Oncology</i> , 2015, 26, 510-516.	1.2	46
68	Shotgun Proteomics on Tissue Specimens Extracted with Acid Guanidinium-Thiocyanate-Phenol-Chloroform. <i>Methods in Molecular Biology</i> , 2015, 1293, 115-122.	0.9	4
69	Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt376.	6.3	77
70	Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naïve estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting. <i>Molecular Oncology</i> , 2014, 8, 1679-1689.	4.6	18
71	Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment. <i>Clinical Cancer Research</i> , 2014, 20, 4816-4826.	7.0	144
72	Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers. <i>Hormones and Cancer</i> , 2014, 5, 405-413.	4.9	140

#	ARTICLE	IF	CITATIONS
73	LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy. <i>Endocrine-Related Cancer</i> , 2014, 21, 101-112.	3.1	82
74	Gene expression profiles of primary tumors versus circulating tumor cells in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11017-11017.	1.6	0
75	<i><sc>KRAS</sc></i> and <i><sc>BRAF</sc></i> mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. <i>International Journal of Cancer</i> , 2013, 133, 130-141.	5.1	128
76	Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 47-57.	2.5	110
77	<i>CCAT2</i>, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. <i>Genome Research</i> , 2013, 23, 1446-1461.	5.5	526
78	Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. <i>British Journal of Cancer</i> , 2013, 108, 1358-1367.	6.4	148
79	KLF6-SV1 Drives Breast Cancer Metastasis and Is Associated with Poor Survival. <i>Science Translational Medicine</i> , 2013, 5, 169ra12.	12.4	70
80	Allele-Specific, Non-Extendable Primer Blocker PCR (AS-NEPB-PCR) for DNA Mutation Detection in Cancer. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 62-69.	2.8	35
81	The challenge of gene expression profiling in heterogeneous clinical samples. <i>Methods</i> , 2013, 59, 47-58.	3.8	18
82	<i>CCAT2</i>, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. <i>Oncotarget</i> , 2013, 4, 1748-1762.	1.8	169
83	A combined EpCAM and MCAM circulating tumor cell (CTC) CellSearch enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists' Group (BOOC) side study.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22106-e22106.	1.6	1
84	mRNA expression profiles in circulating tumor cells (CTCs) of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AI).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11045-11045.	1.6	0
85	High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes. <i>Breast Cancer Research</i> , 2012, 14, R123.	5.0	38
86	CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. <i>Cancer Letters</i> , 2012, 319, 49-55.	7.2	48
87	BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. <i>British Journal of Cancer</i> , 2012, 107, 947-955.	6.4	61
88	The Life History of 21 Breast Cancers. <i>Cell</i> , 2012, 149, 994-1007.	28.9	1,249
89	Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 439-448.	2.5	37
90	Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 843-851.	2.5	46

#	ARTICLE	IF	CITATIONS
91	High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 937-947.	2.5	65
92	A new approach for rapid and reliable enumeration of circulating endothelial cells in patients. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 931-939.	3.8	48
93	Multiplex Molecular Analysis of CTCs. <i>Recent Results in Cancer Research</i> , 2012, 195, 125-140.	1.8	14
94	Hormone replacement therapy dependent changes in breast cancer-related gene expression in breast tissue of healthy postmenopausal women. <i>Molecular Oncology</i> , 2011, 5, 504-516.	4.6	7
95	Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 259-275.	3.1	70
96	Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 387-394.	2.5	46
97	Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 33-41.	2.5	110
98	MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 43-51.	2.5	127
99	Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 23-30.	2.5	83
100	mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 3600-3618.	7.0	207
101	Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. <i>British Journal of Cancer</i> , 2010, 103, 1284-1291.	6.4	111
102	Overexpression of Colligin 2 in Glioma Vasculature is Associated with Overexpression of Heat shock Factor 2. <i>Gene Regulation and Systems Biology</i> , 2010, 4, GRSB.S4546.	2.3	12
103	Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. <i>Endocrine-Related Cancer</i> , 2010, 17, 215-230.	3.1	30
104	Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study. <i>Breast Cancer Research</i> , 2010, 12, R103.	5.0	20
105	Ancestry-Shift Refinement Mapping of the C6orf97-ESR1 Breast Cancer Susceptibility Locus. <i>PLoS Genetics</i> , 2010, 6, e1001029.	3.5	82
106	Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells. <i>Journal of the National Cancer Institute</i> , 2009, 101, 61-66.	6.3	407
107	Relevance of Breast Cancer Antiestrogen Resistance Genes in Human Breast Cancer Progression and Tamoxifen Resistance. <i>Journal of Clinical Oncology</i> , 2009, 27, 542-549.	1.6	93
108	Response: Re: Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells. <i>Journal of the National Cancer Institute</i> , 2009, 101, 896-897.	6.3	10

#	ARTICLE	IF	CITATIONS
109	Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. <i>BMC Genomics</i> , 2009, 10, 424.	2.8	74
110	Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 263-271.	2.5	35
111	The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 303-309.	2.5	134
112	Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 455-468.	2.5	171
113	TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 253-260.	2.5	24
114	Complex landscapes of somatic rearrangement in human breast cancer genomes. <i>Nature</i> , 2009, 462, 1005-1010.	27.8	776
115	CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. <i>British Journal of Cancer</i> , 2009, 101, 1824-1832.	6.4	37
116	Copy Number Alterations that Predict Metastatic Capability of Human Breast Cancer. <i>Cancer Research</i> , 2009, 69, 3795-3801.	0.9	75
117	Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 229-240.	2.5	55
118	DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 429-437.	2.5	103
119	Protein kinase C δ expression in breast cancer as measured by real-time PCR, western blotting and ELISA. <i>British Journal of Cancer</i> , 2008, 99, 1644-1650.	6.4	35
120	Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. <i>Endocrine-Related Cancer</i> , 2008, 15, 101-111.	3.1	59
121	Subtypes of Breast Cancer Show Preferential Site of Relapse. <i>Cancer Research</i> , 2008, 68, 3108-3114.	0.9	674
122	Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response. <i>Clinical Cancer Research</i> , 2008, 14, 5555-5564.	7.0	155
123	Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13021-13026.	7.1	374
124	HOXB13-to-IL17BR Expression Ratio Is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 662-668.	1.6	118
125	Concentrations of TIMP1 mRNA Splice Variants and TIMP-1 Protein Are Differentially Associated with Prognosis in Primary Breast Cancer. <i>Clinical Chemistry</i> , 2007, 53, 1280-1288.	3.2	31
126	Circulating tumour cell detection on its way to routine diagnostic implementation?. <i>European Journal of Cancer</i> , 2007, 43, 2645-2650.	2.8	101

#	ARTICLE	IF	CITATIONS
127	Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer, 2007, 7, 182.	2.6	109
128	Which Cyclin E Prevails as Prognostic Marker for Breast Cancer? Results from a Retrospective Study Involving 635 Lymph Nodeâ€“Negative Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 3319-3328.	7.0	76
129	Genes Associated With Breast Cancer Metastatic to Bone. Journal of Clinical Oncology, 2006, 24, 2261-2267.	1.6	278
130	Multicenter Validation of a Gene Expressionâ€“Based Prognostic Signature in Lymph Nodeâ€“Negative Primary Breast Cancer. Journal of Clinical Oncology, 2006, 24, 1665-1671.	1.6	328
131	Association of DNA Methylation of Phosphoserine Aminotransferase with Response to Endocrine Therapy in Patients with Recurrent Breast Cancer. Cancer Research, 2005, 65, 4101-4117.	0.9	104
132	Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling. Journal of Clinical Oncology, 2005, 23, 732-740.	1.6	322
133	How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study. Clinical Cancer Research, 2005, 11, 7311-7321.	7.0	78
134	Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet, The, 2005, 365, 671-679.	13.7	2,452
135	Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression. Thrombosis and Haemostasis, 2003, 89, 393-404.	3.4	69